» Articles » PMID: 37485446

Ocular Complications of Antineoplastic Therapies

Overview
Journal Future Sci OA
Specialty Biotechnology
Date 2023 Jul 24
PMID 37485446
Authors
Affiliations
Soon will be listed here.
Abstract

Ocular complications of antineoplastic agents can have a profound effect on the quality of life of cancer patients. New oncologic treatments like monoclonal antibodies, immunotherapies, antibody-drug conjugates, checkpoint inhibitors and growth factor receptors have resulted in increased ocular complications. These ocular complications differs in respect to distinct mechanisms of actions and lead to significant challenges in the management of cancer patients. In this review, we reviewed literature, clinical studies and cases detailing ocular complications due to administration of antineoplastic agents and emphasized the need for communication between oncologists and ophthalmologists toward early detection and management of ocular complications.

Citing Articles

Management of severe capecitabine-induced corneal toxicity.

Heyvaert M, Denys H, Van Dorpe J, Roels D Am J Ophthalmol Case Rep. 2024; 36:102174.

PMID: 39319200 PMC: 11421284. DOI: 10.1016/j.ajoc.2024.102174.


Case report: a cataract induced by bleomycin in a patient with testicular cancer.

Zhang W, Ji Y, Sun Y, Zhi K, Yang H, Zhang M Front Pharmacol. 2024; 15:1339662.

PMID: 38966544 PMC: 11222336. DOI: 10.3389/fphar.2024.1339662.


[Staging and systemic treatment of ocular and periocular metastases].

Dorfel D, Babst N, Heindl L, Kakkassery V, Muller M Ophthalmologie. 2024; 121(5):374-381.

PMID: 38683363 DOI: 10.1007/s00347-024-02034-4.


Ocular Surface Side Effects of Novel Anticancer Drugs.

Vitiello L, Lixi F, Coco G, Giannaccare G Cancers (Basel). 2024; 16(2).

PMID: 38254833 PMC: 10814578. DOI: 10.3390/cancers16020344.

References
1.
Caraceni A, Martini C, Spatti G, Thomas A, Onofrj M . Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy. Acta Neurol Scand. 1997; 96(4):260-1. DOI: 10.1111/j.1600-0404.1997.tb00280.x. View

2.
Bukhari D, Alessa S, Beheiri S . Corneal Epithelial Hyperplasia after 5-Fluorouracil Injection. Case Rep Ophthalmol. 2018; 9(1):254-256. PMC: 6082114. DOI: 10.1159/000487474. View

3.
Foerster C, Cursiefen C, Kruse F . Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea. 2008; 27(5):612-4. DOI: 10.1097/ICO.0b013e318166f483. View

4.
Fu C, Gombos D, Lee J, George G, Hess K, Whyte A . Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 2017; 8(35):58709-58727. PMC: 5601686. DOI: 10.18632/oncotarget.17634. View

5.
Wahab A, Rafae A, Mushtaq K, Masood A, Ehsan H, Khakwani M . Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma. Front Oncol. 2021; 11:678634. PMC: 8148346. DOI: 10.3389/fonc.2021.678634. View